INVO Fertility (IVF)
NASDAQ:IVF
Top Page
INVO Fertility
(NASDAQ:IVF)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.00
▲(7.53% Upside)
Action:UpgradedDate:01/28/26
The score is primarily held back by weak financial performance (persistent losses, declining gross margin, and negative operating/free cash flow). Technicals are only mildly supportive, while valuation lacks support due to negative earnings and no dividend data. Corporate events are mixed—growth initiatives and financing help, but dilution risk and the reverse split temper the upside.
Positive Factors
Clinic network expansion via acquisitions
The targeted acquisition adds a revenue-generating clinic and a contractually committed medical director, accelerating scale in a fragmented fertility market. Durable impact: expanded local footprint, incremental recurring procedure revenue, and faster path to operating leverage as clinics integrate into INVO's network.
Negative Factors
Persistent unprofitability and collapsing gross margin
A dramatic gross margin decline and ongoing negative operating profitability point to structural cost pressures or lower service pricing mix. This undermines the company's ability to convert revenue growth into sustainable profits and constrains reinvestment and debt-servicing capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinic network expansion via acquisitions
The targeted acquisition adds a revenue-generating clinic and a contractually committed medical director, accelerating scale in a fragmented fertility market. Durable impact: expanded local footprint, incremental recurring procedure revenue, and faster path to operating leverage as clinics integrate into INVO's network.
Read all positive factors
INVO Fertility (IVF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.25M
Dividend YieldN/A
Average Volume (3M)8.28M
Price to Earnings (P/E)―
Beta (1Y)-0.14
Revenue Growth11.50%
EPS Growth2.37%
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-30.80
Shares Outstanding1,615,419
10 Day Avg. Volume24,408,967
30 Day Avg. Volume8,279,900
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.89
Price to Sales (P/S)7.60
P/FCF Ratio-15.72
Enterprise Value/Market Cap2.10
Enterprise Value/Revenue0.98
Enterprise Value/Gross Profit2.51
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$4.00Price Target Upside330.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-117.6
Revenue Forecast (FY)$7.68M
INVO Fertility Business Overview & Revenue Model
Company Description
INVO Fertility, Inc. operates as a revenue-generating fertility business. It also focuses on the development of class clinical-stage assets in oncology and autoimmune diseases. The company was founded on January 5, 2007 and is headquartered in Sar...
How the Company Makes Money
INVO Fertility generates revenue primarily through the provision of IVF services and related fertility treatments. The company charges patients for various services including initial consultations, diagnostic tests, IVF cycles, egg retrievals, and...
INVO Fertility Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.94M | 6.53M | 3.02M | 822.20K | 4.16M | 1.04M |
| Gross Profit | 2.72M | 2.87M | 1.09M | -28.57K | 4.02M | 948.53K |
| EBITDA | -24.39M | -7.14M | -6.88M | -10.75M | -5.22M | -5.48M |
| Net Income | -28.96M | -9.10M | -8.03M | -10.89M | -6.65M | -8.35M |
Balance Sheet | ||||||
| Total Assets | 18.83M | 46.45M | 18.51M | 3.71M | 10.47M | 10.95M |
| Cash, Cash Equivalents and Short-Term Investments | 355.89K | 741.40K | 232.42K | 90.14K | 5.68M | 10.10M |
| Total Debt | 4.23M | 9.90M | 6.30M | 2.27M | 2.12M | 775.02K |
| Total Liabilities | 12.98M | 33.70M | 17.61M | 4.69M | 3.16M | 5.20M |
| Stockholders Equity | 5.85M | 12.75M | 892.83K | -977.61K | 7.31M | 5.74M |
Cash Flow | ||||||
| Free Cash Flow | -7.77M | -3.16M | -5.20M | -6.62M | -6.48M | -4.86M |
| Operating Cash Flow | -7.66M | -2.97M | -4.76M | -6.60M | -6.03M | -4.78M |
| Investing Cash Flow | 354.98K | 363.89K | -2.49M | -81.22K | -2.15M | -187.25K |
| Financing Cash Flow | 7.19M | 3.12M | 7.39M | 1.09M | 3.77M | 13.82M |
INVO Fertility Technical Analysis
Negative
0.93
Price Trends
4.12
Negative
5.74
Negative
29.30
Negative
Market Momentum
-0.64
Positive
27.86
Positive
14.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVF, the sentiment is Negative. The current price of 0.93 is below the 20-day moving average (MA) of 2.84, below the 50-day MA of 4.12, and below the 200-day MA of 29.30, indicating a bearish trend. The MACD of -0.64 indicates Positive momentum. The RSI at 27.86 is Positive, neither overbought nor oversold. The STOCH value of 14.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVF.
INVO Fertility Risk Analysis
INVO Fertility disclosed 60 risk factors in its most recent earnings report. INVO Fertility reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
INVO Fertility Peers Comparison
UnderperformOutperform
Sector (51)
IVF
INVO Fertility
2.11
-224.69
-99.07%
NIVF
NewGenIvf Group
2.01
-1,202.79
-99.83%
INVO Fertility Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
INVO Fertility Announces Warrant Inducement Financing Agreement
Neutral
Jan 30, 2026
On January 28, 2026, INVO Fertility entered into a warrant inducement agreement with an institutional investor, under which the investor agreed to immediately exercise previously issued December 3, 2025 warrants for 4,733,728 shares at a reduced e...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
INVO Fertility Expands Share Authorization and Equity Flexibility
Positive
Jan 26, 2026
On January 22, 2026, INVO Fertility, Inc. shareholders approved a major increase in authorized common stock from 6,250,000 to 250,000,000 shares and the company filed a corresponding amendment to its Articles of Incorporation the same day, signifi...
Business Operations and StrategyExecutive/Board Changes
INVO Fertility realigns leadership to accelerate clinic growth
Positive
Jan 6, 2026
On December 30, 2025, INVO Fertility announced a realignment of its executive leadership team to better support its growth strategy centered on acquiring and establishing fertility clinics and related businesses. Company controller Terah Krigsvold...
Business Operations and StrategyM&A Transactions
INVO Fertility signs agreement to acquire assets
Positive
Dec 17, 2025
INVO Fertility, Inc. has signed a definitive agreement to acquire the non-clinical assets of Family Beginnings, a well-regarded fertility clinic in Indianapolis, Indiana, for $750,000. The acquisition is expected to close by February 27, 2026, sub...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
INVO Fertility Announces $4M Private Placement Agreement
Positive
Dec 5, 2025
On December 2, 2025, INVO Fertility, Inc. announced a securities purchase agreement with an institutional investor to raise approximately $4 million through a private placement. The company plans to use the proceeds to fund the acquisition of Fami...
Business Operations and StrategyStock Split
INVO Fertility Implements Reverse Stock Split
Positive
Dec 3, 2025
On November 26, 2025, INVO Fertility filed a Certificate of Change to implement a 1-for-8 reverse stock split of its common stock, which became effective on November 28, 2025. This adjustment reduced the number of issued and outstanding shares and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.